Abstract
To assess the impact of achieving Assessment in SpondyloArthritis international Society 40% (ASAS40) response or an Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID) state on patient-reported outcomes (PROs) among patients with non-radiographic axial SpA (nr-axSpA). Data are from ABILITY-1, a phase 3 trial of adalimumab vs placebo in nr-axSpA patients. PROs included the HAQ for Spondyloarthropathies (HAQ-S), 36-item Short Form Health Survey (SF-36) physical component summary (PCS) score and Work Productivity and Activity Impairment Questionnaire. Patients were grouped by clinical response using ASAS40 response and ASDAS disease states at week 12. Changes in PROs from baseline to week 12 were compared between groups using analysis of covariance with adjustment for baseline scores. At week 12, 47 of 179 patients were ASAS40 responders and 26 of 176 patients achieved ASDAS-ID (ASDAS <1.3). Compared with non-responders (n = 132), ASAS40 responders (n = 47) had a significantly greater improvement in mean HAQ-S (-0.65 vs -0.05, P < 0.0001), SF-36 PCS (12.4 vs 0.7, P < 0.0001), presenteeism (-24.7 vs -2.2, P < 0.0001), overall work impairment (-23.9 vs -2.5, P < 0.0001) and activity impairment (-33.5 vs -0.9, P...Continue Reading
References
Jul 18, 1992·BMJ : British Medical Journal·J E BrazierL Westlake
Apr 1, 1984·Arthritis and Rheumatism·S van der LindenA Cats
Oct 5, 1993·PharmacoEconomics·M C ReillyE M Dukes
Jul 15, 1999·Clinical and Experimental Immunology·B D Reilly
Jul 21, 2000·Arthritis and Rheumatism·M KosinskiJ E Ware
Aug 12, 2003·Arthritis and Rheumatism·Rafael Ariza-ArizaFederico Navarro-Sarabia
Mar 5, 2004·Rheumatology·S B CohenJ J Ofman
Mar 17, 2004·Arthritis and Rheumatism·Eswar KrishnanPekka Hannonen
Mar 25, 2004·Rheumatology·V StrandUNKNOWN Leflunomide Investigators Groups
Mar 27, 2004·Annals of the Rheumatic Diseases·J BrandtJ Braun
Feb 5, 2005·Arthritis and Rheumatism·Désirée van der HeijdeUNKNOWN ASsessment in Ankylosing Spondylitis International Working Group
Aug 1, 2007·Arthritis and Rheumatism·John C DavisMichelle P Luo
Sep 11, 2007·Health and Quality of Life Outcomes·Sepideh S FarivarRon D Hays
Jun 26, 2008·Arthritis and Rheumatism·Hildrun HaibelJoachim Sieper
Jul 16, 2008·Annals of the Rheumatic Diseases·C LukasUNKNOWN Assessment of SpondyloArthritis international Society
Aug 15, 2008·Annals of the Rheumatic Diseases·D van der HeijdeUNKNOWN ATLAS Study Group
Dec 9, 2008·Annals of the Rheumatic Diseases·D van der HeijdeUNKNOWN Assessment of SpondyloArthritis international Society (ASAS)
Feb 28, 2009·Arthritis and Rheumatism·Martin RudwaleitJoachim Sieper
May 21, 2009·Annals of the Rheumatic Diseases·M RudwaleitJ Sieper
Dec 4, 2009·The Journal of Rheumatology·Walter P MaksymowychDésirée van der Heijde
Aug 14, 2010·International Journal of Rheumatic Diseases·Kemal NasSalih Ozgocmen
Nov 12, 2010·Annals of the Rheumatic Diseases·Pedro MachadoUNKNOWN Assessment of SpondyloArthritis international Society
Jul 5, 2011·The Journal of Rheumatology·Pedro M M C MachadoDésirée M van der Heijde
Apr 24, 2012·Annals of the Rheumatic Diseases·U KiltzJ Braun
Jul 10, 2012·Annals of the Rheumatic Diseases·Joachim SieperAileen L Pangan
Jun 7, 2013·Annals of the Rheumatic Diseases·M M SchoelsD van der Heijde
Jun 12, 2013·Annals of the Rheumatic Diseases·Josef S SmolenDésirée van der Heijde
Sep 10, 2013·Annals of the Rheumatic Diseases·R LandewéJ Sieper
Jun 4, 2014·Arthritis & Rheumatology·Maxime DougadosJack F Bukowski
Citations
Oct 18, 2016·Rheumatology and Therapy·Keith A BettsArijit Ganguli
Mar 29, 2018·Arthritis Research & Therapy·Désirée van der HeijdeAileen L Pangan
Sep 8, 2017·Modern Rheumatology·Sara MontiRoberto Caporali
Nov 21, 2017·Rheumatology·Miranda van LunterenFloris A van Gaalen
Jan 15, 2017·Annals of the Rheumatic Diseases·Désirée van der HeijdeJürgen Braun
Aug 6, 2017·Clinical Reviews in Allergy & Immunology·Ennio LubranoFabio Massimo Perrotta
Mar 17, 2018·The Journal of Rheumatology·Miranda van LunterenFloris A van Gaalen
May 16, 2019·Current Opinion in Rheumatology·Pedro M Machado, Atul Deodhar
Dec 20, 2018·RMD Open·Jürgen BraunUNKNOWN MEASURE 1 and MEASURE 2 study groups
Jun 19, 2017·Arthritis Research & Therapy·Lonneke van HoevenAngelique E A M Weel
Nov 26, 2019·International Journal of Rheumatic Diseases·Kee Fong PhangPeter P Cheung
Jul 29, 2020·Current Rheumatology Reports·Elena Nikiphorou, Sofia Ramiro
Sep 15, 2020·Clinical Rheumatology·John D ReveilleAtul Deodhar
Sep 15, 2017·Cost Effectiveness and Resource Allocation : C/E·Stephanie HarvardAslam Anis
Aug 25, 2017·Therapeutic Advances in Musculoskeletal Disease·Valeria Rios Rodriguez, Denis Poddubnyy
Jan 9, 2017·Rheumatology·Johan K WallmanLars E Kristensen
Jun 24, 2020·Rheumatology·Augusta OrtolanDésirée van der Heijde
Oct 27, 2016·Arthritis Care & Research·P A C BakkerF A van Gaalen
Jan 5, 2020·Health and Quality of Life Outcomes·Maxime DougadosMiriam Tarallo
Dec 31, 2016·Rheumatology International·Andrew KeatTamara Everiss
Apr 8, 2020·BMC Musculoskeletal Disorders·Tom NadinChristopher J Edwards
Sep 1, 2018·Rheumatology International·Fernando Andres SommerfleckGustavo Citera
Oct 9, 2020·Medicine·Eon Jeong Nam, Won Kee Lee
Oct 1, 2019·Rheumatic Diseases Clinics of North America·Elena Nikiphorou, Xenofon Baraliakos
Oct 15, 2020·Rheumatology·Xabier MichelenaHelena Marzo-Ortega
Dec 22, 2020·Therapeutic Advances in Musculoskeletal Disease·Katharina MeierKamran Ghoreschi
Jan 28, 2021·Rheumatology·Xabier MichelenaHelena Marzo-Ortega
Jun 28, 2021·Rheumatology·Esther BeckersAstrid van Tubergen